Manitol Hztm (Mannitol)

Mannitol acts by remaining largely unmetabolized in the renal tubules, creating an osmotic gradient that pulls water from the bloodstream into the urine. This osmotic diuresis increases fluid excretion, reduces plasma volume, and consequently decreases pressure within the skull and the eye by limiting fluid accumulation.

The specific dose and infusion rate of Manitol Hztm are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Dosing regimens are individualized and should follow the prescriber’s instructions and institutional protocols.

Safety data for Mannitol in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and use is recommended only when the potential benefits outweigh any potential risks to the mother or fetus. Breastfeeding mothers should consult their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Manitol Hztm. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Mannitol is the most widely used osmotic diuretic for rapid pressure reduction, offering a predictable osmotic effect and a well‑characterized safety profile. Compared with hypertonic saline, Mannitol provides a stronger osmotic gradient with less risk of hyperchloremic acidosis, though both require careful monitoring of electrolytes and fluid balance.

Manitol Hztm should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration, and allow the container to reach room temperature if required for infusion preparation.

Manitol Hztm is administered intravenously, typically as a controlled infusion over a specified period. The infusion rate is set by the prescriber and may be adjusted based on patient response, urine output, and serum osmolality. Administration should occur in a monitored clinical environment.

Serious adverse events include pulmonary edema, severe electrolyte disturbances such as hypernatremia or hyperkalemia, acute worsening of renal failure, and rare anaphylactic reactions. Prompt recognition of respiratory distress, abrupt changes in fluid balance, or severe electrolyte shifts is essential for patient safety.

Manitol Hztm is contraindicated in patients with known hypersensitivity to Mannitol, severe dehydration, active intracranial bleeding, or uncontrolled heart failure. Caution is also advised for individuals with severe renal impairment, as the drug’s clearance may be markedly reduced.